2004
Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer
Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O’Reilly M, Hong WK, Fidler IJ, Putnam JB, Herbst RS. Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer. Clinical Cancer Research 2004, 10: 136-143. PMID: 14734462, DOI: 10.1158/1078-0432.ccr-0373-3.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma, Bronchiolo-AlveolarAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDisease ProgressionErbB ReceptorsFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesLung NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPhosphorylationPrognosisReceptor, ErbB-2Retrospective StudiesRisk FactorsSurvival RateTransforming Growth Factor alphaConceptsStage I non-small cell lung cancerNon-small cell lung cancerEpidermal growth factor receptorCell lung cancerSquamous cell carcinomaHER2-neuGrowth factor alphaPhosphorylated epidermal growth factor receptorGrowth factor receptorCell carcinomaLung cancerFactor alphaPathological stage I non-small cell lung cancerFactor receptorPotential prognostic factorsShorter overall survivalPatients' clinical outcomesSynchronous overexpressionHER2-neu overexpressionLung cancer progressionMaximal therapyMetastatic diseaseOverall survivalPrognostic factorsClinical outcomes
2003
P-484 Synchronous overexpression of epidermal growth factor receptor and HER2-NEU is a predictor of poor outcome in patients with stage I non-small cell lung cancer
Onn A, Correa A, Gilcrease M, Massarelli E, Bucana C, Hong W, Fidler I, Putnam J, Herbst R. P-484 Synchronous overexpression of epidermal growth factor receptor and HER2-NEU is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Lung Cancer 2003, 41: s213. DOI: 10.1016/s0169-5002(03)92451-2.Peer-Reviewed Original Research